These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. Zanwar S; Kumar S Leuk Lymphoma; 2021 Dec; 62(13):3087-3097. PubMed ID: 34304677 [TBL] [Abstract][Full Text] [Related]
47. High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy. Rees MJ; Kumar S Am J Hematol; 2024 Aug; 99(8):1560-1575. PubMed ID: 38613829 [TBL] [Abstract][Full Text] [Related]
48. Disturbed MAPK pathway in early bilateral testicular extramedullary relapse of multiple myeloma. Huang HF; Xu J; Xu AS; Wan XY; Chen L; Fan FJ; Zhang B; Tang L; Chen WX; Sun X; Ai LS; Hou J; Sun CY; Hu Y Leuk Res; 2020 Aug; 95():106403. PubMed ID: 32569928 [No Abstract] [Full Text] [Related]
49. Race-based differences in routine cytogenetic profiles of patients with multiple myeloma. Blue BJ; Luo S; Sanfilippo KM; Ganti A; Gumbel J; O'Brian K; Carson KR Br J Haematol; 2017 Jan; 176(2):322-324. PubMed ID: 26887893 [No Abstract] [Full Text] [Related]
50. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis. Soliman AM; Das S; Teoh SL Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299097 [TBL] [Abstract][Full Text] [Related]
51. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Zhou Y; Barlogie B; Shaughnessy JD Leukemia; 2009 Nov; 23(11):1941-56. PubMed ID: 19657360 [TBL] [Abstract][Full Text] [Related]
52. A rational approach to functional high-risk myeloma. Gay F; Bertuglia G; Mina R Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):433-442. PubMed ID: 38066896 [TBL] [Abstract][Full Text] [Related]
53. Multiple myeloma with central nervous system relapse. Egan PA; Elder PT; Deighan WI; O'Connor SJM; Alexander HD Haematologica; 2020 Jul; 105(7):1780-1790. PubMed ID: 32414852 [TBL] [Abstract][Full Text] [Related]
54. Myeloma Is Not a Single Disease. Lonial S; Nooka AK J Oncol Pract; 2016 Apr; 12(4):287-92. PubMed ID: 27072380 [TBL] [Abstract][Full Text] [Related]
58. The biological features of multiple myeloma. Michaeli J; Choy CG; Zhang X Cancer Invest; 1997; 15(1):76-84. PubMed ID: 9028393 [No Abstract] [Full Text] [Related]
59. International Myeloma Working Group recommendations for global myeloma care. Ludwig H; Miguel JS; Dimopoulos MA; Palumbo A; Garcia Sanz R; Powles R; Lentzsch S; Ming Chen W; Hou J; Jurczyszyn A; Romeril K; Hajek R; Terpos E; Shimizu K; Joshua D; Hungria V; Rodriguez Morales A; Ben-Yehuda D; Sondergeld P; Zamagni E; Durie B Leukemia; 2014 May; 28(5):981-92. PubMed ID: 24177258 [TBL] [Abstract][Full Text] [Related]
60. Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes. Tanguay M; Dagenais C; LeBlanc R; Ahmad I; Claveau JS; Roy J Curr Oncol; 2023 May; 30(6):5214-5226. PubMed ID: 37366879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]